SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
1. Faruqi & Faruqi is investigating claims against SRPT. 2. A class action alleges SRPT misled investors about ELEVIDYS safety. 3. Recent deaths associated with ELEVIDYS significantly impacted SRPT's stock price. 4. Investors may contact Faruqi & Faruqi regarding potential claims. 5. FDA is investigating ELEVIDYS safety amid rising scrutiny.